On estimating the mean of the selected normal population in two-stage adaptive designs

Adaptive design is widely used in clinical trials. In this paper, we consider the problem of estimating the mean of the selected normal population in two-stage adaptive designs. Under the LINEX and L₂ loss functions, admissibility and minimax results are derived for some location invariant estimators of the selected normal mean. The naive sample mean estimator is shown to be inadmissible under the LINEX loss function and to be not minimax under both loss functions.     

Optimal two-stage designs for phase ii clinical trials with differentiation of complete and partial responses

In the usual design and analysis of a phase II trial, there is no differentiation between complete response and partial response. Since complete response is considered more desirable this paper proposes a weighted score method which extends Simon's (1989) two-stage design to the situation where the complete and partial responses are differentiated. The weight assigned to the complete response is suggested by examining the likelihood ratio (LR) statistic for testing a simple hypothesis of a trinomial distribution. Both optimal and minimax designs are tabulated for a wide range of design parameters. The weighted score approach is shown to give more efficient designs, especially when the response probability is moderate to large.     

Minimax A-, c-, and I-optimal regression designs for models with heteroscedastic errors

It is well known that it is difficult to construct minimax optimal designs. Furthermore, since in practice we never know the true error variance, it is important to allow small deviations and construct robust optimal designs. We investigate a class of minimax optimal regression designs for models with heteroscedastic errors that are robust against possible misspecification of the error variance. Commonly used A-, c-, and I-optimality criteria are included in this class of minimax optimal designs. Several theoretical results are obtained, including a necessary condition and a reflection symmetry for these minimax optimal designs. In this article, we focus mainly on linear models and assume that an approximate error variance function is available. However, we also briefly discuss how the methodology works for nonlinear models. We then propose an effective algorithm to solve challenging nonconvex optimization problems to find minimax designs on discrete design spaces. Examples are given to illustrate minimax optimal designs and their properties.     

Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis

two‐stage studies may be chosen optimally by minimising a single characteristic like the maximum sample size. However, given that an investigator will initially select a null treatment e?ect and the clinically relevant di?erence, it is better to choose a design that also considers the expected sample size for each of these values. The maximum sample size and the two expected sample sizes are here combined to produce an expected loss function to ?nd designs that are admissible. Given the prior odds of success and the importance of the total sample size, minimising the expected loss gives the optimal design for this situation. A novel triangular graph to represent the admissible designs helps guide the decision‐making process. The H ₀‐optimal, H ₁‐optimal, H ₀‐minimax and H ₁‐minimax designs are all particular cases of admissible designs. The commonly used H ₀‐optimal design is rarely good when allowing stopping for e?cacy. Additionally, the δ‐minimax design, which minimises the maximum expected sample size, is sometimes admissible under the loss function. However, the results can be varied and each situation will require the evaluation of all the admissible designs. Software to do this is provided. Copyright © 2012 John Wiley & Sons, Ltd.     

D-optimal minimax design criterion for two-level fractional factorial designs

A D-optimal minimax design criterion is proposed to construct two-level fractional factorial designs, which can be used to estimate a linear model with main effects and some specified interactions. D-optimal minimax designs are robust against model misspecification and have small biases if the linear model contains more interaction terms. When the D-optimal minimax criterion is compared with the D-optimal design criterion, we find that the D-optimal design criterion is quite robust against model misspecification. Lower and upper bounds derived for the loss functions of optimal designs can be used to estimate the efficiencies of any design and evaluate the effectiveness of a search algorithm. Four algorithms to search for optimal designs for any run size are discussed and compared through several examples. An annealing algorithm and a sequential algorithm are particularly effective to search for optimal designs.     

A semi-infinite programming based algorithm for finding minimax optimal designs for nonlinear models

Minimax optimal experimental designs are notoriously difficult to study largely because the optimality criterion is not differentiable and there is no effective algorithm for generating them. We apply semi-infinite programming (SIP) to solve minimax design problems for nonlinear models in a systematic way using a discretization based strategy and solvers from the General Algebraic Modeling System (GAMS). Using popular models from the biological sciences, we show our approach produces minimax optimal designs that coincide with the few theoretical and numerical optimal designs in the literature. We also show our method can be readily modified to find standardized maximin optimal designs and minimax optimal designs for more complicated problems, such as when the ranges of plausible values for the model parameters are dependent and we want to find a design to minimize the maximal inefficiency of estimates for the model parameters.     

An MSE‐reduced estimator for the response proportion in a two‐stage clinical trial

Two‐stage design is very useful in clinical trials for evaluating the validity of a specific treatment regimen. When the second stage is allowed to continue, the method used to estimate the response rate based on the results of both stages is critical for the subsequent design. The often‐used sample proportion has an evident upward bias. However, the maximum likelihood estimator or the moment estimator tends to underestimate the response rate. A mean‐square error weighted estimator is considered here; its performance is thoroughly investigated via Simon's optimal and minimax designs and Shuster's design. Compared with the sample proportion, the proposed method has a smaller bias, and compared with the maximum likelihood estimator, the proposed method has a smaller mean‐square error. Copyright © 2010 John Wiley & Sons, Ltd.     

Adaptive designs for selecting drug combinations based on efficacy–toxicity response

We propose a new adaptive procedure for dose-finding in clinical trials with combination of two drugs when both efficacy and toxicity responses are available. We model the distribution of this bivariate binary endpoint using the bivariate probit model. The analytic formulae for the Fisher information matrix are obtained, that form the basis for derivation of the locally optimal, minimax, Bayesian, and adaptive designs in the framework of optimal design theory.     

Bayesian two-stage design for drug screening trials with switching hypothesis tests based on continuous endpoints

Abstract

In this paper, we propose a Bayesian two-stage design with changing hypothesis test by bridging a single-arm study and a double-arm randomized trial in one phase II clinical trial based on continuous endpoints rather than binary endpoints. We have also calibrated with respect to frequentist and Bayesian error rates. The proposed design minimizes the Bayesian expected sample size if the new candidate has low or high efficacy activity subject to the constraint upon error rates in both frequentist and Bayesian perspectives. Tables of designs for various combinations of design parameters are also provided.     

Bayesian single-arm phase II trial designs with time-to-event endpoints

For the cancer clinical trials with immunotherapy and molecularly targeted therapy, time-to-event endpoint is often a desired endpoint. In this paper, we present an event-driven approach for Bayesian one-stage and two-stage single-arm phase II trial designs. Two versions of Bayesian one-stage designs were proposed with executable algorithms and meanwhile, we also develop theoretical relationships between the frequentist and Bayesian designs. These findings help investigators who want to design a trial using Bayesian approach have an explicit understanding of how the frequentist properties can be achieved. Moreover, the proposed Bayesian designs using the exact posterior distributions accommodate the single-arm phase II trials with small sample sizes. We also proposed an optimal two-stage approach, which can be regarded as an extension of Simon's two-stage design with the time-to-event endpoint. Comprehensive simulations were conducted to explore the frequentist properties of the proposed Bayesian designs and an R package BayesDesign can be assessed via R CRAN for convenient use of the proposed methods.     

A confidence function-based posterior probability design for phase II cancer trials

Single-arm one- or multi-stage study designs are commonly used in phase II oncology development when the primary outcome of interest is tumor response, a binary variable. Both two- and three-outcome designs are available. Simon two-stage design is a well-known example of two-outcome designs. The objective of a two-outcome trial is to reject either the null hypothesis that the objective response rate (ORR) is less than or equal to a pre-specified low uninteresting rate or to reject the alternative hypothesis that the ORR is greater than or equal to some target rate. Three-outcome designs proposed by Sargent et al. allow a middle gray decision zone which rejects neither hypothesis in order to reduce the required study size. We propose new two- and three-outcome designs with continual monitoring based on Bayesian posterior probability that meet frequentist specifications such as type I and II error rates. Futility and/or efficacy boundaries are based on confidence functions, which can require higher levels of evidence for early versus late stopping and have clear and intuitive interpretations. We search in a class of such procedures for optimal designs that minimize a given loss function such as average sample size under the null hypothesis. We present several examples and compare our design with other procedures in the literature and show that our design has good operating characteristics.     

Optimal designs for exponential regression

This paper is concerned with the optimal design problem for the particular case of non-linear parametrisation:the parameters to be estimated are included in exponents.Some properties of locally optimal designs as functions of estimated parameters are investigated and a table of such designs in given.We consider also designs to be optimal in the sense of minimax approach.     

Three-stage designs for monitoring clinical trials

Optimal three-stage designs with equal sample sizes at each stage are presented and compared to fixed sample designs, fully sequential designs, designs restricted to use the fixed sample critical value at the final stage, and to modifications of other group sequential designs previously proposed in the literature. Typically, the greatest savings realized with interim analyses are obtained by the first interim look. More than 50% of the savings possible with a fully sequential design can be realized with a simple two-stage design. Three-stage designs can realize as much as 75% of the possible savings. Without much loss in efficiency, the designs can be modified so that the critical value at the final stage equals the usual fixed sample value while maintaining the overall level of significance, alleviating some potential confusion should a final stage be necessary. Some common group sequential designs, modified to allow early acceptance of the null hypothesis, are shown to be nearly optimal in some settings while performing poorly in others. An example is given to illustrate the use of several three-stage plans in the design of clinical trials.     

Efficient estimators for adaptive stratified sequential sampling

In stratified sampling, methods for the allocation of effort among strata usually rely on some measure of within-stratum variance. If we do not have enough information about these variances, adaptive allocation can be used. In adaptive allocation designs, surveys are conducted in two phases. Information from the first phase is used to allocate the remaining units among the strata in the second phase. Brown et al. [Adaptive two-stage sequential sampling, Popul. Ecol. 50 (2008), pp. 239–245] introduced an adaptive allocation sampling design – where the final sample size was random – and an unbiased estimator. Here, we derive an unbiased variance estimator for the design, and consider a related design where the final sample size is fixed. Having a fixed final sample size can make survey-planning easier. We introduce a biased Horvitz–Thompson type estimator and a biased sample mean type estimator for the sampling designs. We conduct two simulation studies on honey producers in Kurdistan and synthetic zirconium distribution in a region on the moon. Results show that the introduced estimators are more efficient than the available estimators for both variable and fixed sample size designs, and the conventional unbiased estimator of stratified simple random sampling design. In order to evaluate efficiencies of the introduced designs and their estimator furthermore, we first review some well-known adaptive allocation designs and compare their estimator with the introduced estimators. Simulation results show that the introduced estimators are more efficient than available estimators of these well-known adaptive allocation designs.     

Two-stage phase II trials with early stopping for effectiveness and safety as well as ineffectiveness or harm

This article proposes new optimal and minimax designs, which allow early stopping not only for ineffectiveness or toxicity but also for sufficient effectiveness and safety. These designs may facilitate effective drug development by detecting sufficient effectiveness and safety at an early stage or by detecting ineffectiveness or excessive toxicity at an early stage. The proposed design has advantage over other designs in the sense that it can control the type I error rate and is robust against the real association parameter. Comparing to Jin's design, it is always advantageous in terms of expected sample size.     

A relaxation procedure for calculating (G–)minimax optimal designs

Summary: In nonlinear statistical models, standard optimality functions for experimental designs depend on the unknown parameters of the model. An appealing and robust concept for choosing a design is the minimax criterion. However, so far, minimax optimal designs have been calculated efficiently under various restrictive conditions only. We extend an iterative relaxation scheme originally proposed by Shimizu and Aiyoshi (1980) and prove its convergence under very general assumptions which cover a variety of situations considered in experimental design. Application to different specific design criteria is discussed and issues of practical implementation are addressed. First numerical results suggest that the method may be very efficient with respect to the number of iterations required.*Supported by a grant from the Deutsche Forschungsgemeinschaft. We are grateful to a referee for his constructive suggestions.     

Spatial sampling design for parameter estimation of the covariance function

We study the spatial optimal sampling design for covariance parameter estimation. The spatial process is modeled as a Gaussian random field and maximum likelihood (ML) is used to estimate the covariance parameters. We use the log determinant of the inverse Fisher information matrix as the design criterion and run simulations to investigate the relationship between the inverse Fisher information matrix and the covariance matrix of the ML estimates. A simulated annealing algorithm is developed to search for an optimal design among all possible designs on a fine grid. Since the design criterion depends on the unknown parameters, we define relative efficiency of a design and consider minimax and Bayesian criteria to find designs that are robust for a range of parameter values. Simulation results are presented for the Matérn class of covariance functions.     

Constrained design strategies for improving normal approximations in nonlinear regression problems

In nonlinear regression problems, the assumption is usually made that parameter estimates will be approximately normally distributed. The accuracy of the approximation depends on the sample size and also on the intrinsic and parameter-effects curvatures. Based on these curvatures, criteria are defined here that indicate whether or not an experiment will lead to estimates with distributions well approximated by a normal distribution. An approach is motivated of optimizing a primary design criterion subject to satisfying constraints based on these nonnormality measures. The approach can be used either to I) find designs for a fixed sample size or to II) choose the sample size for the optimal design based on the primary objective so that the constraints are satisfied. This later objective is useful as the nonnormality measures decrease with the sample size. As the constraints are typically not concave functions over a set of design measures, the usual equivalence theorems of optimal design theory do not hold for the first approach, and numerical implementation is required. Examples are given, and a new notation using tensor products is introduced to define tractable general notation for the nonnormality measures.     

Minimax Designs for the Stability of Slope Estimation on Second-order Response Surfaces

In this paper, designs for the stability of the slope estimation on a second-order response surface are considered. Minimization of the point dispersion measure, which is maximized over all points in the region of interest is taken as the optimality criterion, and the minimax properties in some class of designs are derived in spherical and cubic regions of interest. We study the efficiencies of the minimax designs relative to other optimal designs with various criteria.     

Adaptive choice of scale tests in flexible two-stage designs with applications in experimental ecology and clinical trials

In this paper, the two-sample scale problem is addressed within the rank framework which does not require to specify the underlying continuous distribution. However, since the power of a rank test depends on the underlying distribution, it would be very useful for the researcher to have some information on it in order to use the possibly most suitable test. A two-stage adaptive design is used with adaptive tests where the data from the first stage are used to compute a selector statistic to select the test statistic for stage 2. More precisely, an adaptive scale test due to Hall and Padmanabhan and its components are considered in one-stage and several adaptive and non-adaptive two-stage procedures. A simulation study shows that the two-stage test with the adaptive choice in the second stage and with Liptak combination, when it is not more powerful than the corresponding one-stage test, shows, however, a quite similar power behavior. The test procedures are illustrated using two ecological applications and a clinical trial.